

Field JJ, Majerus E, Gordeuk VR, et al. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. *Blood Adv.* 2017;1(20):1645-1649.

In the "Acknowledgments" section on page 1648 of the 12 September 2017 issue, an acknowledgment of support from Charles T. Quinn, Jeffrey Keefer, Paul Swerdlow, and Marilyn Telen was missing. Also, the author initials associated with grants R01 HL098526 and P50HL110790 should have been excluded, because the grants funded more individuals than originally indicated. The errors have been corrected in the published article.

---

DOI 10.1182/bloodadvances.2017012922

© 2017 by The American Society of Hematology